EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

EKF Diagnostics Holdings Plc (EKF) fair value: what the stock is really worth

As of Sep 28, 2026: fair value of EKF Diagnostics Holdings Plc £0.27, price £0.25, upside +8.9%, quality 70 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · GB · ISIN GB0031509804

ED Thin data Sep 27, 2026

EKF Diagnostics Holdings Plc

EKF · LSE

NeutralQuality growthThe stock looks roughly fairly valued with average quality.

·Fair value £0.2684 · Fairly valued (+8.9%)
✓Quality 70/100
!Weak Growth (revenue 5y −4.6 %/yr)
!Thin margins · 4.1% net margin (TTM)
✓Low debt · generates free cash flow
✓Ranks above peers (8/13)
!Narrow moat 40/100
!Insider activity 40/100
!Evidence only low, so the estimate is less certain
!Weak on future: 27 out of 100
!Weak on past: 14 out of 100
Watch EKF Diagnostics Holdings Plc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

£0.7821 £0.1875 Fair Value £0.2684 Jul 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range £0.1875 – £0.7821 · fair‑value band £0.1867 – £0.3501 · the £0.2465 price screens below the £0.2684 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 27, 2026.

Follow EKF Diagnostics Holdings in your weekly email

Every Wednesday you see whether EKF Diagnostics Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally.

Show more

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm analyzer; Hemo Control, a hemoglobin analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab HbA1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test HbA1c, fully automated hemoglobin A1c analyzer for the monitoring and management of diabetes; and STAT-Site W Beta-Hydroxybutyrate analyzer. In addition, the company offers Creamatocrit Plus, a breast milk analyzer; QuPID and True20 pregnancy tests; Lactate Scout Vet, a handheld lactate analyzer for veterinary care; Hemo Vet, a point-of-care hemoglobin and hematocrit analyzer; Lactate Scout Sport, a lactate analyzer for sports performance; Biosen series for sports; and EKF Link, a data management solution that integrates point-of-care analyzers. Further, it offers Beta-Hydroxybutyrate LiquiColor for monitoring ketosis; RaPET, a range of immunoassay kits; QuStick Strep A for Strep A infection treatment; Hema-Screen Lab Pack for detection of colorectal cancer; PrimeStore MTM, a molecular transport medium that preserves and stabilizes DNA and RNA; Uri-Trak 120M urine analyzer; and clinical chemistry reagents, controls, and standards. Additionally, the company provides precision fermentation, custom bioprocessing, and contract manufacturing solutions; and diagnostic enzymes that include arylacylamidase, beta-hydroxybutyrate dehydrogenase, and salicylate hydroxylase. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.

Stock analysis

EKF Diagnostics Holdings Plc (EKF) currently trades at £0.2465, while our model-based Fair Value estimate is £0.2684, so the stock looks roughly fairly valued today (gap 8.2%).

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of £0.3700 per share, and 12 of the 24 models we run sit above the £0.2465 price.

Bear case: the Economic Profit group reads lowest at £0.1000, and 12 of the 24 models stay below the price. Evidence for this calculation is low.

Scenario range: £0.1867 (bear) to £0.3501 (bull), the price of £0.2465 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

EKF Diagnostics Holdings Plc reported revenue of £51.6M in FY2025 versus £81.8M in FY2021, a compound −10.9%/yr. Reported net income was £2.1M in FY2025, compounding −39.5%/yr from FY2021.

Key figures

Market cap 111M GBX · P/S ratio 2.10 · Net margin 4.1% · Return on equity 3.5% · Return on assets (EBIT) 9.2% · Operating margin 12.9% · Revenue (TTM) £51.6M · Revenue growth (YoY) +5.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 44 out of 100 (low confidence).

What moves the price

The share trades about 20% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 9%, EKF screens cheaper than that median.

Fair Value models

Bear £0.1867 Fair Value £0.2684 Bull £0.3501
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF £0.2600 £0.3600 £0.6200 76
Growth DCF £0.2500 £0.3800 £0.5900 75
EPV £0.0900 £0.1000 £0.1100 74
All 24 models by family
DCF Models
FCF DCF £0.2600 £0.3600 £0.6200 76
Owner Earnings £0.1900 £0.3500 £0.6100 71
5Y Revenue Exit £0.2200 £0.3300 £0.5700 68
5Y EBITDA Exit £0.3100 £0.5200 £0.9300 70
5Y P/E Exit £0.1700 £0.2800 £0.4200 68
10Y Revenue Exit £0.2300 £0.4100 £0.5200 65
10Y EBITDA Exit £0.2900 £0.5800 £1.09 63
10Y P/E Exit £0.2000 £0.3300 £0.5100 61
Earnings-Based
Graham-Dodd £0.0300 £0.2300 £0.3300 61
Lynch FV £0.1200 £0.1700 £0.2200 59
PEG = 1.0 £0.1200 £0.1700 £0.2200 55
EPV £0.0900 £0.1000 £0.1100 74
Multiples
P/E Multiple £0.0800 £0.1100 £0.1400 63
P/S Multiple £0.0600 £0.0800 £0.1000 58
P/B Multiple £0.0600 £0.0800 £0.1000 55
EV/EBIT £0.2400 £0.3000 £0.3700 66
EV/EBITDA £0.3300 £0.4300 £0.5300 67
EV/Revenue £0.1800 £0.2400 £0.3000 54
Asset-Based
NCAV (Graham) £0.0800 £0.1100 £0.1600 54
Growth DCF
Growth DCF £0.2500 £0.3800 £0.5900 75
Rev-Margin DCF £0.2300 £0.3700 £0.6700 68
Economic Profit
Residual Income £0.1000 £0.1000 £0.1000 68
ROIC Compounder £0.0900 £0.1000 £0.1100 70
Growth Earnings
Growth-Adj P/E £0.1600 £0.2300 £0.3000 65

Open the full fair value analysis →

Notify me when EKF reaches fair value

Put EKF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 70/100

Of which business quality 71 · Market factors (momentum, volatility) 41

Profitability 37
Margins and returns on capital today
Quality Growth 37
Are margins and returns improving?
Cashflow 80
Earnings quality: real cash, not paper profit
Fin. Strength 93
Balance sheet, leverage, solvency risk
Investment 98
Disciplined investing over empire-building
Low Volatility 70
Calm price path (market factor)
Momentum 33
Price trend over the last 3–12 months (market factor)
52W Momentum 22
Distance to the 52-week high (market factor)
Net Issuance 91
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+2.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.6%
Start year 2020 (pandemic). Over 10 years: +5.5% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.4%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
−16.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−16.4%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.26% → 13%

Growth Forecast

Price in line with expectations
The price assumes more growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+4.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+6.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (UK: IMF forecast 2.3% a year to 2030, 3.3% from 2016 to 2025) that is about +1.6% a year for the price and +3.6% for the forecasts.
Forecast 2026 (sales)+5.9%
Forecast 2027 (sales)+6.9%
Projected 2028 (sales)+6.3%
Projected 2029 (sales)+5.7%
Projected 2030 (sales)+5.1%

Watch EKF, get fair value alerts →

Compare EKF Diagnostics Holdings Plc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 364 stocks

Beats the industry median on 7/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 70 · Top 25%
Fair Value upside +8.9% · Above median
Profitability
Return on equity (TTM) 3.5% · Above median
Return on assets 5.4% · Top 25%
Net margin (TTM) 4.1% · Below median
Operating margin (TTM) 12.9% · Above median
Growth and dividend
Revenue growth 5.4% · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (TTM) 52.5× · Priciest 25%
P/B 2.12× · Pricier than median
P/S (TTM) 2.84× · Pricier than median
P/FCF 17.9× · Cheaper than median
EV/EBITDA 12.9× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)45 · sector 10
FUTURE (revenue growth)27 · sector 31
PAST (return on equity)14 · sector 8
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 38

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $101.29 $74.79 −26%
Medtronic plc MDT $88.64 $65.61 −26%
Stryker Corporation SYK $272.36 $299.60 +10%
Boston Scientific Corporation BSX $43.92 $48.31 +10%
Edwards Lifesciences Corporation EW $86.29 $81.94 −5%
Siemens Healthineers AG SHL €37.79 €35.19 −7%
DexCom, Inc DXCM $86.62 $95.28 +10%
GE HealthCare Technologies Inc GEHC $66.63 $70.37 +6%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥153.86 ¥169.25 +10%
Koninklijke Philips N.V PHIA €21.87 €15.23 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

EKF Diagnostics Holdings Plc · Fair Value
£0.2684 +8%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "EKF Diagnostics Holdings Plc Fair Value". https://www.fairvalue-calculator.com/stock/EKF

Frequently asked questions

Is EKF Diagnostics Holdings Plc (EKF) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of £0.2684 versus a price of £0.2465, about +9% upside (fairly valued).
What is the fair value of EKF?
Our model-based fair value for EKF Diagnostics Holdings Plc is £0.2684 (as of Sep 27, 2026), built from audited fundamentals. The current price: £0.2465.
What is the quality score of EKF?
EKF Diagnostics Holdings Plc has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for EKF Diagnostics Holdings Plc (EKF)?
Our model-based price target is the fair value of £0.2684 (as of Sep 27, 2026) from 24 valuation models. Cautious scenario £0.1867, optimistic scenario £0.3501. It is a calculation from audited fundamentals, not an analyst target.
What is the EKF Diagnostics Holdings Plc stock forecast for 2026?
Our models put fair value at £0.2684, about +9% upside versus a price of £0.2465 (fairly valued). Cautious scenario £0.1867, optimistic scenario £0.3501. The calculation is refreshed regularly with new filings.
What is the revenue of EKF Diagnostics Holdings Plc (EKF)?
EKF Diagnostics Holdings Plc reported trailing-twelve-month revenue of about £51.6M (latest available figure, as of Sep 27, 2026).
What growth is priced into EKF Diagnostics Holdings Plc (EKF)?
For today's price to be fair in a discounted-cash-flow model, EKF Diagnostics Holdings Plc would have to grow free cash flow by +4.0 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -4.6 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of EKF use?
Our models discount EKF Diagnostics Holdings Plc at 11.8 %: a base by market capitalisation (micro), damped by beta 0.51, country premium for United Kingdom. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For EKF Diagnostics Holdings Plc that is +4.0 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has EKF Diagnostics Holdings Plc (EKF) delivered so far?
Over the past 5 years revenue at EKF Diagnostics Holdings Plc grew -4.6 % a year. The price currently implies +4.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of EKF Diagnostics Holdings Plc (EKF) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into EKF Diagnostics Holdings Plc (+4.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of EKF Diagnostics Holdings Plc (EKF)?
The free-cash-flow yield on the price is 7.40 %: that much free cash flow EKF Diagnostics Holdings Plc produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of EKF Diagnostics Holdings Plc (EKF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For EKF Diagnostics Holdings Plc it is £0.2684 per share (as of Sep 27, 2026), against a price of £0.2465. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is EKF Diagnostics Holdings Plc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, EKF trades below its calculated fair value: price £0.2465, fair value £0.2684, a gap of about +9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EKF?
No. The price is what the market pays today (£0.2465); the fair value is what the company's own numbers justify (£0.2684). For EKF Diagnostics Holdings Plc the two are £0.0219 per share apart. That gap is exactly why we show both numbers side by side.
How much is EKF Diagnostics Holdings Plc worth?
The market values EKF Diagnostics Holdings Plc at about 111M GBX (market capitalisation, as of Sep 27, 2026). Per share that is £0.2465; our models calculate a fair value of £0.2684 per share.
What do the bullish and bearish scenarios say about EKF?
Our models span a range for EKF Diagnostics Holdings Plc: cautious scenario £0.1867, base £0.2684, optimistic £0.3501 per share (as of Sep 27, 2026, price £0.2465). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of EKF?
EKF Diagnostics Holdings Plc trades at a price-to-earnings ratio of 52.5 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of £0.2684 is built from several models across several years. Other multiples: P/B 2.1, P/S 2.8, EV/EBITDA 12.9.
How solid is the balance sheet of EKF Diagnostics Holdings Plc (EKF)?
Balance-sheet figures for EKF Diagnostics Holdings Plc (as of Sep 27, 2026): return on equity 3.5%. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is EKF from its 52-week high?
EKF Diagnostics Holdings Plc trades at £0.2465, about 20% below its 52-week high of £0.3100 and 13% above the low of £0.2180 (as of Sep 28, 2026). Distance from the high says nothing about value: that is what the fair value of £0.2684 is for.
Which stocks are comparable to EKF Diagnostics Holdings Plc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is EKF Diagnostics Holdings Plc stock attractive at the current price?
The data as of Sep 27, 2026: price £0.2465, calculated fair value £0.2684 (+9%), Quality Score 70/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EKF calculated?
We run EKF Diagnostics Holdings Plc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of £0.2684, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.9 % above its aggregate fair value. EKF Diagnostics Holdings Plc currently trades 9 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of EKF Diagnostics Holdings Plc (EKF)?
The closing price on Sep 28, 2026 was £0.2465. Our model-based fair value is £0.2684, about +9% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with EKF Diagnostics Holdings Plc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (£0.1867 to £0.3501) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of EKF Diagnostics Holdings Plc

How large is the market capitalisation of EKF Diagnostics Holdings Plc (EKF)?
The market capitalisation of EKF Diagnostics Holdings Plc is 111M GBX. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of EKF Diagnostics Holdings Plc (EKF)?
The price-to-sales ratio of EKF Diagnostics Holdings Plc is 2.10 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of EKF Diagnostics Holdings Plc (EKF)?
The net margin of EKF Diagnostics Holdings Plc is 4.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of EKF Diagnostics Holdings Plc (EKF)?
The return on equity (ROE) of EKF Diagnostics Holdings Plc is 3.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of EKF Diagnostics Holdings Plc (EKF)?
On an EBIT basis the return on assets of EKF Diagnostics Holdings Plc is 9.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of EKF Diagnostics Holdings Plc (EKF)?
The operating margin of EKF Diagnostics Holdings Plc is 12.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at EKF Diagnostics Holdings Plc (EKF)?
Revenue at EKF Diagnostics Holdings Plc is growing +5.4% versus a year earlier (3y avg −8.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at EKF Diagnostics Holdings Plc (EKF)?
Earnings per share at EKF Diagnostics Holdings Plc are growing −96.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does EKF Diagnostics Holdings Plc (EKF) hold?
EKF Diagnostics Holdings Plc holds more cash than debt, 14.4M GBX net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch EKF Diagnostics Holdings Plc in the live analysis

One click puts EKF Diagnostics Holdings Plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.